BRKR BRUKER CORP

CIK 0001109354 50 ready 8-Ks latest May 6, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing May 29, 2026, 4:10 PM ET

Top materiality 0.85

Event mix earnings ×21 · other_material ×8 · leadership ×6

Sentiment 17 pos · 7 neg · 26 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for BRKR

Highest-materiality recent filing

Bruker Q4 revenue flat, FY25 GAAP loss $0.15; guides FY26 non-GAAP EPS up 15-17%

February 12, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Q4-25 revenues $977.2M, flat YoY (-0.2%), organic decline 5.1%; GAAP EPS $0.10, non-GAAP EPS $0.59.
FY25 revenues $3.44B (+2.1% reported, -3.7% organic); GAAP diluted loss $(0.15), non-GAAP EPS $1.83.

Read filing →

May 6, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Bruker Q1 revenue $823.4M (+2.7% reported, -4.4% organic); GAAP EPS $0.02

Q1-26 GAAP diluted EPS $0.02 (vs $0.11 YoY); non-GAAP diluted EPS $0.31 (vs $0.47 YoY).
April 10, 2026, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

Bruker BioSpin President Falko Busse to depart; separation includes ~$1M severance

Falko Busse, Ph.D., to step down as President of Bruker BioSpin; duties transition May 1, 2026, employment ends Oct 31, 2026.
February 12, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Bruker Q4 revenue flat, FY25 GAAP loss $0.15; guides FY26 non-GAAP EPS up 15-17%

Q4-25 revenues $977.2M, flat YoY (-0.2%), organic decline 5.1%; GAAP EPS $0.10, non-GAAP EPS $0.59.
January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 7.01

Bruker prelim Q4 2025 revenue $965-970M; FY26 outlook flat to low-single-digit organic growth

Q4 2025 preliminary revenue $965-970M; scientific instruments book-to-bill above 1.0.
November 3, 2025, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Bruker Q3 revenue $860.5M (-0.5% YoY); GAAP loss $0.41/share; cuts FY25 EPS guidance to $1.85-1.90

Q3 GAAP diluted loss per share $(0.41); non-GAAP diluted EPS $0.45 vs $0.60 a year ago.
September 8, 2025, 7:59 PM ET other material materiality 0.70 neutral item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Bruker closes $690M 6.375% mandatory convertible preferred stock offering

Issued 2.76M shares of Series A mandatory convertible preferred (BRKRP) at $250 liquidation preference per share, total $690M.
August 4, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Bruker Q2 revenue $797M, -0.4% YoY; non-GAAP EPS $0.32, -38.5%; lowers FY2025 guidance

Q2 revenue $797.4M, organic -7.0% YoY from weak US academic and biopharma demand.
July 21, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Bruker pre-announces Q2 preliminary EPS $0.32-$0.34, down ~$0.19 YoY

Preliminary Q2 2025 revenue $795-$798M, roughly flat YoY reported; constant-currency revenue down ~3%.
May 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07 item 9.01

Bruker stockholders approve 2026 Incentive Compensation Plan authorizing 12M shares

Stockholders approved 2026 Plan with 12M shares authorized (6M new + ~5M carryover from 2016 Plan). Effective Feb 19, 2026.
May 14, 2025, 7:59 PM ET litigation materiality 0.75 positive item 8.01 item 9.01

Bruker and 10x Genomics settle all global patent litigation with cross-license agreements

Settlement resolves all patent disputes between Bruker and 10x Genomics, including multiple litigations in US, Germany, and European Unified Patent Court.
May 7, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Bruker Q1 revenues up 11% but EPS falls; lowers FY2025 guidance on tariff and market headwinds

Q1 revenues $801.4M, up 11.0% YoY; GAAP diluted EPS $0.11, non-GAAP diluted EPS $0.47 (down 11.3% YoY).
April 11, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Bruker pre-announces Q1 2025 revenue: $795M-$800M, ~10% YoY growth, beating outlook

Preliminary Q1 2025 revenue range $795M-$800M; reported growth ~10% YoY, low-double digit constant-exchange-rate growth.
February 13, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Bruker Q4 revenue $979.6M (+14.6% YoY); FY 2025 guidance implies 11-13% EPS growth

Q4 revenue $979.6M (+14.6% YoY); organic +3.9%; GAAP EPS $0.09; non-GAAP EPS $0.76 (+8.6%).
January 13, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01

Bruker sees Q4 2024 revenue of $970M-$980M; 2025 outlook of upper mid-single digit growth

Preliminary Q4 2024 revenue guidance of $970M to $980M (unaudited, subject to change).
November 5, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Bruker Q3 revenue up 16.4% but GAAP EPS $0.27 down from $0.60; FY2024 guidance lowered

Q3 revenue $864.4M, up 16.4% YoY; organic growth 3.1%, CER growth 15.7%.
August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Bruker Q2 revenue $800.7M (+17.4% YoY), raises FY2024 revenue guidance to $3.38-$3.44B

Q2 revenue $800.7M, up 17.4% YoY; organic revenue growth 7.4%.
May 31, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

Bruker launches 6M-share offering at $67.29 to repay acquisition-related debt

Offering of 6,000,000 shares at $67.29 per share; underwriters have 30-day option for 900,000 additional shares.
May 2, 2024, 7:59 PM ET M&A materiality 0.85 positive item 7.01 item 9.01

Bruker completes €870M cash acquisition of ELITechGroup; expects $0.08-0.10 EPS accretion

Purchase price of €870 million in cash for ELITech, excluding clinical chemistry business.
May 2, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Bruker Q1 revenue $721.7M (+5.3% YoY); GAAP EPS falls to $0.35; FY24 guidance raised $60M

Q1 revenue $721.7M (+5.3% YoY); organic revenue up 1.6%.
April 22, 2024, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Bruker to acquire NanoString assets for $392.6M in cash; expected to close Q2 2024

Bruker to acquire substantially all NanoString assets for $392.6M cash, including nCounter, GeoMx, CosMx and AtoMx product lines.
April 2, 2024, 7:59 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 9.01 ◈ Debt Financings ×3◈ Material Agreements

Bruker enters CHF 450M term loan facilities (3/5/7-year) for general corporate purposes

Entered CHF 150M three-year, CHF 150M five-year, and CHF 150M seven-year term loan facilities on March 29, 2024.
February 13, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Bruker Q4 revenue $854.5M (+20.6%); FY 2024 organic growth 5-7%

Q4 2023 revenue $854.5M, up 20.6% YoY; organic revenue +15.9%.
February 12, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 9.01 ◈ Debt Financings◈ Material Agreements

Bruker Corp enters note purchase agreement for CHF 100M senior notes due 2036/2039

CHF 50M 2.60% Series A Senior Notes due April 15, 2036 and CHF 50M 2.62% Series B due April 15, 2039.
January 8, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 ◈ Earnings Releases ×2

Bruker prelim Q4 rev >$830M, FY2023 >$2.94B; guides 2024 above-market organic growth

Preliminary Q4 2023 revenue >$830M with organic growth >12% YoY; FY2023 revenue >$2.94B with organic growth >13% YoY.
December 26, 2023, 6:59 PM ET M&A materiality 0.85 positive item 1.01 item 7.01

Bruker agrees to acquire ELITechGroup for €870M enterprise value; Q2 2024 close expected

Enterprise Value of €870 million; cash purchase price with cash on hand.
November 2, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Bruker Q3: Rev $742.8M, Non-GAAP EPS $0.74, FY organic guidance raised to 11.5-12.5%

Q3 revenue $742.8M (+16.3% YoY); organic +10.9%, acquisitions +2.1%, FX +3.3%.
August 3, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Bruker Q2 revenue $681.9M (+15.9% YoY); raises FY23 revenue guidance to $2.85-2.90B

Q2 revenue $681.9M (+15.9% YoY, organic +13.5%); GAAP EPS $0.39, non-GAAP EPS $0.50 (+11.1% YoY).
May 15, 2023, 7:59 PM ET other materiality 0.65 positive item 8.01 item 9.01

Bruker authorizes up to $500M share repurchase over two years, declares $0.05 dividend

Board approved $500M share buyback from May 15, 2023 to May 14, 2025.
May 4, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Bruker Q1 rev $685.3M (+15.2% YoY, organic +17.6%); GAAP EPS $0.52, non-GAAP $0.64

Q1 2023 revenue $685.3M, up 15.2% YoY; organic revenue growth 17.6% YoY.
February 9, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases ×3

Bruker Q4 non-GAAP EPS $0.74 (+25% YoY); FY23 organic growth guidance 8-10%

Q4 revenues $708.4M (+3.6% reported, +8.9% organic); GAAP EPS $0.66 vs $0.50.
November 3, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×3

Bruker Q3 organic revenue up 12.7%; raises FY2022 organic growth and margin guidance

Q3 revenue $638.9M, +4.9% reported, +12.7% organic YoY. Non-GAAP EPS $0.66, up 4.8%.

Executive changes

Appointed

Laura Francis

director

BRKR · BRUKER CORP

Effective: 2025-02-18
Filed: February 21, 2025, 6:59 PM ET

appointed Laura Francis to fill the newly created vacancy on the Board, effective as of February 18, 2025.

Appointed

Thomas Bures

Chief Accounting Officer

BRKR · BRUKER CORP

Effective: 2025-01-13
Filed: January 16, 2025, 6:59 PM ET

On January 13, 2025, Thomas Bures was appointed to serve as the Chief Accounting Officer of Bruker Corporation (the “Company”), effective immediately.

Departed

Philip Ma

Director

BRKR · BRUKER CORP

Effective: 2024-08-05
Filed: August 7, 2024, 7:59 PM ET

On August 5, 2024, Dr. Philip Ma informed the board of directors (the “Board”) of Bruker Corporation (the “Company”) of his resignation from the Board, effective immediately, to concentrate his efforts on his own company.

Departed

Marc Kastner

Director

BRKR · BRUKER CORP

Filed: March 16, 2022, 7:59 PM ET

Dr. Marc Kastner informed the Board of Directors (“Board”) of Bruker Corporation (the “Company”) of his decision to retire and not to stand for re-election as a Class II director when his current term expires at the Company’s 2023 Annual Meeting of Stockholders

Appointed

Philip Ma

Director

BRKR · BRUKER CORP

Effective: 2022-04-01
Filed: March 16, 2022, 7:59 PM ET

the Board approved an increase in the number of directors to expand the size of the Board by one director to a total of eleven directors, with such additional director assigned to Class II, and appointed Dr. Philip Ma to fill the newly created vacancy on the Board, effective as of April 1, 2022.

Earnings & guidance

2026-Q1 EPS reported $0.02 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

17 positive 7 negative 26 neutral

source · BRKR on sec.gov